By admin 
The recent announcement by the Department of Defense regarding a mandatory testosterone screening program for service members represents a seismic shift in military health policy and a provocative entry into a long-standing medical debate. When Defense Secretary Pete Hegseth confirmed on Wednesday that the Department of Defense (DOD) would begin screening service members aged 30 and older for testosterone levels, the news immediately reverberated through the medical and veteran communities. For those of us who have dedicated our careers to studying men’s health and the intricacies of population-level screening, this directive raises a series of urgent questions. The implementation of such a widespread rollout may lead to surprising and unintended consequences that must be meticulously weighed against the perceived benefits of "optimizing" the health and readiness of U.S. servicemembers.
As a practicing urologist and health outcomes researcher, I have witnessed the meteoric rise of interest in testosterone supplementation over the last decade. This interest is not confined to clinical settings; it has permeated popular culture, fitness communities, and now, the highest echelons of national defense. However, the decision to mandate screening for a hormone as complex as testosterone is historically unprecedented. While the goal of ensuring a "fit and ready" force is noble, the medical reality of testosterone deficiency—and the risks of its treatment—is far more nuanced than a simple blood test might suggest.
To understand the gravity of this policy, one must first understand the biological machinery at play. Testosterone is the primary male sex hormone, but it is not a standalone actor. Its levels are the product of a highly sensitive and complex feedback loop known as the hypothalamic-pituitary-gonadal (HPG) axis. This system involves the brain (the hypothalamus and pituitary gland) communicating with the testes to regulate hormone production. The HPG axis is responsible for male reproductive development in utero, the physiological transformations of puberty, and the maintenance of bone density, muscle mass, and libido throughout adulthood. It is also intrinsically linked to behavioral characteristics, including aggression and drive, which are often cited by proponents of testosterone therapy in a military context.
However, testosterone levels are not static. They are subject to significant diurnal variation—peaking in the early morning—and are influenced by a myriad of external factors including sleep quality, stress, diet, and body composition. Furthermore, it is a well-established biological fact that testosterone levels naturally decline as men age. This "andropause," or late-onset hypogonadism, often mirrors the symptoms of general aging: increased body fat, decreased bone density (osteoporosis), and reduced energy. The challenge for clinicians is distinguishing between the natural effects of aging and a true pathological deficiency. This distinction is further blurred by the fact that conditions like obesity, sedentary lifestyles, and chronic stress—all of which can be present in a high-pressure military environment—can themselves suppress testosterone levels.
The backdrop for the DOD’s new mandate is a global testosterone replacement therapy (TRT) market that has experienced explosive growth. In the late 1980s, global sales of testosterone products were a mere $18 million annually. By 2025, that figure is projected to reach nearly $2 billion. This surge has been driven by several factors: the aging Baby Boomer and Gen X populations, direct-to-consumer marketing, and the rise of "wellness" influencers and online prescribing platforms. These digital marketplaces often operate with looser regulations than traditional urology clinics, sometimes resulting in patients obtaining medications without proper supervision. In my own practice, I have seen patients who, through these online channels, achieved testosterone levels many times higher than the physiological "normal" range, placing them at significant risk for complications.
There is no denying that for men with a true clinical deficiency, TRT can be transformative. It can increase lean muscle mass, improve libido, and enhance mood and cognitive function. For a soldier, these might seem like the ultimate performance-enhancing benefits. But medical intervention is rarely a "free lunch." The risks associated with testosterone supplementation are well-documented and, in some cases, severe.
The history of TRT research is marked by caution. In 2010, the Testosterone in Older Men with Mobility Limitations (TOM) study was famously halted early by safety monitors. The reason was a significantly higher incidence of major adverse cardiovascular events—including heart attacks and strokes—among the men receiving testosterone compared to those on a placebo. While more recent data, such as the 2023 TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men), offered some reassurance by showing that TRT was not necessarily worse than placebo regarding major cardiac events, it also uncovered new red flags. The TRAVERSE study found a higher incidence of acute kidney injury, atrial fibrillation (a dangerous heart rhythm disorder), and pulmonary embolism (blood clots in the lungs) among those taking the hormone.
My own research group has focused specifically on the impacts of TRT within the military population. Utilizing data from beneficiaries covered by TRICARE, the military’s health insurance system, we conducted DOD-supported studies to track long-term health outcomes. Our findings added further layers of complexity to the debate. We observed higher rates of kidney stones and obstructive sleep apnea among military members using testosterone supplementation. While one of our studies did show a correlation with improved cardiovascular outcomes in certain subsets, the overall picture remains one of significant trade-offs.
Perhaps the most critical concern for a younger demographic—specifically those in their 30s—is the impact of testosterone therapy on fertility. Exogenous testosterone (testosterone taken as a supplement) acts as a form of male contraception. By flooding the system with external hormones, the body’s natural HPG axis shuts down, leading to a dramatic decrease in sperm count and a physical shrinking of the testicles. Both the American Urological Association (AUA) and the Endocrine Society guidelines explicitly caution against the use of testosterone in men who still plan to father children. For a 30-year-old service member, this is not a minor side effect; it is a life-altering medical consequence that must be discussed before any screening program begins.
The implementation of the DOD’s mandate also poses a staggering logistical and clinical challenge. Testosterone measurement is notoriously finicky. A single low reading is insufficient for a diagnosis of hypogonadism. Clinical best practices require at least two separate blood draws, taken in the early morning (usually before 10:00 AM) when levels are at their peak. These must be analyzed alongside other markers, such as Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), to determine if the issue is with the testes or the brain. Furthermore, men must be screened for contraindications before starting therapy. Those with untreated sleep apnea, a high risk for prostate cancer, severe heart failure, or thrombophilia (a predisposition to blood clots) could see their conditions dangerously exacerbated by TRT.
The current Endocrine Society guidelines are quite clear: they recommend against routine, population-level screening of asymptomatic men for hypogonadism. They also advise against routine supplementation for younger men who may have low levels but do not have a specific underlying disorder of the hypothalamic-pituitary system. The DOD’s directive, therefore, appears to be in direct contradiction to established clinical guidelines.
Secretary Hegseth noted that while screening is mandatory, the decision to take supplements would remain with the individual service member. However, "choice" in a military context is a complicated concept. If a service member is told their levels are "low" and that "optimization" could improve their performance, the pressure to medicate may be immense. To ensure this is handled ethically, the DOD must provide robust, individualized counseling that incorporates each member’s physiology, family planning goals, and risk factors.
Scaling such a personalized approach to the entire Department of Defense health system will be an administrative and medical feat of massive proportions. It requires not just testing, but long-term monitoring of red blood cell counts (to check for polycythemia, a thickening of the blood), prostate-specific antigen (PSA) levels, and cardiovascular health. Without this infrastructure, the program risks becoming a "pill mill" that prioritizes short-term performance over long-term health.
The decision to roll out widespread population-level testing in U.S. service members represents a novel experiment without any clear precedent in modern medicine. We are essentially entering uncharted territory, where the biological baseline of our fighting force is being subjected to mass pharmacological intervention. For the wellness of our military members, it is critical that this program is not viewed as a simple "fix" for aging or fatigue. It must be accompanied by rigorous oversight and a commitment to clinical safety that matches the intensity of the screening itself. As we move forward, we must remember that the health of a service member is measured by more than just a number on a lab report; it is defined by a complex balance of physical capability, long-term vitality, and the preservation of their future quality of life.
